Kaken Pharma forecasts FY2026 net sales at 89,900 million yen, operating profit at 7,900 million yen

• Kaken set FY2026 consolidated net sales guidance at JPY 89.9 billion, up JPY 13.03 billion, or 16.9%.
• FY2026 operating profit forecast at JPY 7.9 billion; ordinary profit seen at JPY 8.6 billion; profit forecast at JPY 6.5 billion.
• Guidance follows FY2026 1Q net sales of JPY 30.15 billion, up 59.8%, with operating profit of JPY 10.9 billion.
• FY2026 1Q overseas sales rose to JPY 14.49 billion from JPY 1.74 billion; overseas sales ratio climbed to 48.1% from 9.2%.
• FY2026 consolidated capital expenditures plan set at JPY 2.1 billion, down JPY 1.58 billion, or 43%.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kaken Pharmaceutical Co. Ltd. published the original content used to generate this news brief on August 07, 2026, and is solely responsible for the information contained therein.